EFI Lake Geneva Ventures

Founded in 2019, AnnAidA Technologies specializes in developing innovative devices for biochemical research. Its flagship product, EmbryoSpin, enables chemical analysis at the scale of a single human embryo using microscopic Nuclear Magnetic Resonance technology.

Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform that utilizes magnetic blood purification technology to address infections and other health ailments. Hemotune's innovative approach involves the use of magnetic beads, which facilitate the selective and efficient removal of large biomolecules from the bloodstream. This technology focuses on the immunological aspects of conditions like sepsis, allowing for targeted treatment that addresses multiple disease pathways. By enhancing the purification of blood in acute care settings, Hemotune aims to improve patient outcomes for those suffering from blood-related diseases.

Hylomorph is a MedTech company that develops biomaterial solutions to improve the interface between implantable medical devices and biological tissue. Its technology includes a cellulose film designed to prevent fibrotic encapsulation and adhesion, helping to reduce postoperative complications such as fibrosis, infection, and device migration, thereby aiming to lower implant failure. The approach combines biotech with surface micro-engineering to optimize tissue implant interaction. First indications target cardiac devices like pacemakers and defibrillators, as well as neurostimulators. The company was founded in 2014 and is headquartered in Zurich, Switzerland.

EBAMed develops a non-invasive ultrasound-based device to monitor and treat heart motion using proton beams. Founded in 2018, the company is based in Geneva, Switzerland.

Seprify develops and sells cellulose-based white pigments and opacifiers, aiming to replace titanium dioxide in various industries. Their plant-derived solutions are renewable, biocompatible, and scalable, promoting sustainability and safety in product manufacturing.

FluoSphera is a biotechnology company focused on developing safer and more effective drugs. It aims to minimize adverse side effects and reduce reliance on animal testing by leveraging innovative drug discovery technologies. This enables FluoSphera's partners to better understand human physiological responses and safeguard populations from harmful chemicals more efficiently.

Terapet specializes in advanced proton therapy for cancer treatment. Founded by physicists Christina Vallgren, Marcus Palm, and Professor Raymond Miralbell from Geneva University Hospitals, the company offers precise radiotherapy that minimizes harm to healthy cells. Incorporated in 2019, Terapet is based in Geneva, Switzerland.